GLP-1 medications (such as semaglutide and related drugs) became widely known for helping people lose weight by increasing fullness and reducing appetite. Now, a growing body of research and clinical observation is raising a second, surprising possibility: these drugs may also reduce certain addictive behaviors, including problematic alcohol and drug use. At the same time, newer analyses highlight an important reality for weight management—many people regain weight after stopping GLP-1 therapy, sometimes quickly.

This article summarizes what the latest reporting and early evidence indicate, what scientists think might be happening in the brain and body, and how to think about GLP-1s as part of a long-term health plan rather than a short-term fix.

What are GLP-1 drugs?

GLP-1 receptor agonists mimic (or amplify) the effects of a naturally occurring gut hormone involved in appetite regulation and blood-sugar control. In practical terms, these medicines can:

  • Increase satiety (you feel full sooner and longer)
  • Slow stomach emptying, which can reduce hunger between meals
  • Improve glucose regulation, which can help stabilize energy and cravings for some people

Although many people associate GLP-1s primarily with weight loss, several were originally developed for type 2 diabetes, and the broader metabolic effects have driven interest in additional therapeutic uses.

Why researchers are looking at GLP-1s for addiction

Multiple recent reports describe accumulating evidence that GLP-1 drugs may reduce cravings and compulsive reward-seeking—patterns that overlap with addiction. The rationale is not that these medicines “cure” addiction, but that they may influence biological pathways involved in:

  • Reward processing (the brain’s motivation/reinforcement circuits)
  • Impulsivity and cue reactivity (how strongly triggers drive behavior)
  • Craving intensity (the felt urge to consume alcohol, drugs, or other rewarding substances)

Some observational findings and early studies have suggested lower rates of alcohol use or other substance-related outcomes among people taking GLP-1s compared with similar groups not taking them. News coverage also describes clinicians noting reduced interest in alcohol or other “rewarding” habits in some patients.

Important caveat

Evidence is still developing. Many signals come from observational data (which can be influenced by confounding factors) and early-stage research. That means GLP-1s are not yet a standard, stand-alone treatment for substance use disorders. Larger randomized trials and longer follow-up are needed to clarify who might benefit, for which substances, at what doses, and with what risks.

How could GLP-1s affect addiction biology?

Researchers are exploring several plausible mechanisms:

  • Brain reward pathways: GLP-1 receptors exist in areas of the brain involved in reinforcement and reward. Activating these receptors may dampen the rewarding “hit” from substances or reduce the drive to seek them.
  • Appetite–craving overlap: Hunger, cravings, and reward behaviors share neurochemical and hormonal signals. By shifting appetite signaling, GLP-1s may indirectly reduce certain cravings.
  • Improved metabolic stability: Better blood-sugar control and reduced swings in hunger can lower stress on the body, which may reduce some craving patterns for certain people.

These explanations are still being tested, but they help interpret why a medication designed for metabolic health could plausibly influence broader reward-driven behaviors.

What happens when you stop GLP-1 weight-loss medication?

Several recent analyses emphasize a recurring pattern: many people regain weight after discontinuing GLP-1 therapy. In some studies and real-world reports, weight regain can be rapid, especially in the first months after stopping. At the same time, not all progress is necessarily lost—some findings suggest a portion of weight loss may persist for some individuals.

Why regain happens is straightforward: the medication’s appetite- and satiety-modulating effects diminish when the drug is removed, and the body tends to defend its prior weight through increased hunger signals and reduced energy expenditure. If a person stops without a plan to replace the “support” the medication provided (nutrition strategy, activity, sleep, stress management, and sometimes alternative medications), the biology can pull weight back up.

Why some people may feel “worse off than before”

Beyond weight regain, stopping can be psychologically and physically discouraging. People may experience:

  • Return of stronger hunger and cravings
  • Loss of the structure or confidence they had while on treatment
  • Frustration that can trigger rebound eating or reduced activity

This doesn’t mean GLP-1s are a bad option—it means they often function more like long-term therapy for a chronic condition than a temporary “course.”

Practical guidance if you’re considering GLP-1s (or stopping them)

1) Treat obesity and addiction risk as long-term health issues

If GLP-1s are helping with weight or cravings, it may be useful to think in terms of ongoing management. For many people, the key question becomes: “What is my long-term plan—medication, lifestyle, monitoring, and support?” rather than “How fast can I get off this?”

2) Don’t stop abruptly without a clinician plan

Talk with your prescriber about:

  • Whether tapering is appropriate (depending on the specific drug and your situation)
  • How to adjust nutrition and protein intake to protect muscle mass
  • How to structure activity to support appetite regulation and weight maintenance
  • Whether another therapy is needed to reduce rebound hunger

3) If addiction is a concern, keep evidence-based care central

If you struggle with alcohol or drug use, proven treatments—counseling, peer support, medications specifically indicated for substance use disorders, harm reduction strategies, and mental health care—should remain the foundation. GLP-1s, if ultimately validated, would most likely be an adjunct for some patients, not a replacement for comprehensive care.

4) Watch for unrealistic expectations from social-media narratives

Celebrity weight-loss stories can drive interest, but individual outcomes vary widely based on starting weight, underlying health conditions, dose and adherence, side effects, and support systems. Focus on clinically meaningful metrics (blood pressure, glucose, lipids, functional fitness, sleep, mental health) rather than only dramatic transformations.

Bottom line

GLP-1 medications are reshaping weight management, and emerging evidence suggests they might also reduce cravings and certain addictive behaviors for some people. However, the addiction-related benefits are not yet definitive, and stopping GLP-1 therapy commonly leads to weight regain unless there’s a strong maintenance strategy. If you’re using—or considering—these medications, the safest approach is to plan for long-term management with medical supervision, realistic expectations, and supportive lifestyle and mental health care.